Progenics Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 47 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Progenics Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Progenics Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Progenics Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Progenics Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Progenics Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Progenics Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Progenics Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

- Evaluate Progenics Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Progenics Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Progenics Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Progenics Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Progenics Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Progenics Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Progenics Pharmaceuticals, Inc. Snapshot 5
Progenics Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Progenics Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Progenics Pharmaceuticals, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Progenics Pharmaceuticals, Inc. - Pipeline Products Glance 13
Progenics Pharmaceuticals, Inc. - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
Progenics Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Progenics Pharmaceuticals, Inc. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Progenics Pharmaceuticals, Inc. - Drug Profiles 17
methylnaltrexone bromide 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Edotreotide Labeled Yttrium 90 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
iobenguane I 131 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
PSMA ADC 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
MIP-1095 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
MIP-1375 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
MIP-1407 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
PSMA-KLH Conjugate Vaccines 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Progenics Pharmaceuticals, Inc. - Pipeline Analysis 30
Progenics Pharmaceuticals, Inc. - Pipeline Products by Target 30
Progenics Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 32
Progenics Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 33
Progenics Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 34
Progenics Pharmaceuticals, Inc. - Recent Pipeline Updates 35
Progenics Pharmaceuticals, Inc. - Dormant Projects 41
Progenics Pharmaceuticals, Inc. - Discontinued Pipeline Products 42
Discontinued Pipeline Product Profiles 42
PRO-206 42
PSMA VRP Vaccine 42
Progenics Pharmaceuticals, Inc. - Company Statement 43
Progenics Pharmaceuticals, Inc. - Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables
Progenics Pharmaceuticals, Inc., Key Information 5
Progenics Pharmaceuticals, Inc., Key Facts 5
Progenics Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8
Progenics Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9
Progenics Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10
Progenics Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014 11
Progenics Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 12
Progenics Pharmaceuticals, Inc. - Phase III, 2014 13
Progenics Pharmaceuticals, Inc. - Phase II, 2014 14
Progenics Pharmaceuticals, Inc. - Preclinical, 2014 15
Progenics Pharmaceuticals, Inc. - Discovery, 2014 16
Progenics Pharmaceuticals, Inc. - Pipeline by Target, 2014 31
Progenics Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 32
Progenics Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 33
Progenics Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 34
Progenics Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 35
Progenics Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 41
Progenics Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 42
Progenics Pharmaceuticals, Inc., Subsidiaries 45